Treace Medical Concepts, Inc. Payments to Acquire Debt Securities, Available-for-sale
Treace Medical Concepts, Inc. (TMCI) reported Payments to Acquire Debt Securities, Available-for-sale of $18.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-07
- Treace Medical Concepts, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $2.60M, a 82.86% decline year-over-year.
- Treace Medical Concepts, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $16.07M, a 6.50% increase year-over-year.
- Treace Medical Concepts, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $5.68M, a 69.60% decline year-over-year.
- Treace Medical Concepts, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $4.64M, a 80.81% decline year-over-year.
- Treace Medical Concepts, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $40.57M, a 43.32% decline from fiscal 2024.
- Treace Medical Concepts, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $71.58M, a 57.86% decline from fiscal 2023.
- Treace Medical Concepts, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $169.87M, a 167.89% increase from fiscal 2022.
- Treace Medical Concepts, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $63.41M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $18.67M 10-Q · filed 2026-08-07 | $24.35M derived: sum of 3 quarters · filed 2026-08-07 | $28.99M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $16.07M 10-Q · filed 2026-05-08 | $21.75M derived: sum of 2 quarters · filed 2026-05-08 | $26.39M derived: sum of 3 quarters · filed 2026-05-08 | $41.55M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $5.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $10.32M derived: sum of 2 quarters · filed 2026-02-27 | $25.48M derived: sum of 3 quarters · filed 2026-08-07 | $40.57M 10-K · filed 2026-02-27 |
| 2025-09-30 | $4.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $19.80M derived: sum of 2 quarters · filed 2026-08-07 | $34.89M 10-Q · filed 2025-11-06 | $53.58M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $15.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $30.25M 10-Q · filed 2026-08-07 | $48.94M derived: sum of 3 quarters · filed 2026-08-07 | $73.12M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $15.09M 10-Q · filed 2026-05-08 | $33.78M derived: sum of 2 quarters · filed 2026-05-08 | $57.96M derived: sum of 3 quarters · filed 2026-05-08 | $57.96M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $18.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $42.87M derived: sum of 2 quarters · filed 2026-02-27 | $42.87M derived: sum of 3 quarters · filed 2026-02-27 | $71.58M 10-K · filed 2026-02-27 |
| 2024-09-30 | $24.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $24.18M derived: sum of 2 quarters · filed 2025-11-06 | $52.89M 10-Q · filed 2025-11-06 | $82.68M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $28.71M 10-Q · filed 2025-08-07 | $58.50M derived: sum of 3 quarters · filed 2026-02-27 | $77.62M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $28.71M 10-Q · filed 2025-05-08 | $58.50M derived: sum of 2 quarters · filed 2026-02-27 | $77.62M derived: sum of 3 quarters · filed 2026-02-27 | $99.03M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $29.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $48.91M derived: sum of 2 quarters · filed 2026-02-27 | $70.31M derived: sum of 3 quarters · filed 2026-02-27 | $169.87M 10-K · filed 2026-02-27 |
| 2023-09-30 | $19.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $40.52M derived: sum of 2 quarters · filed 2024-11-05 | $140.07M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $21.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $120.96M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $99.55M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $63.41M 10-K · filed 2025-02-27 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |